Table 2 Pooled analysis and subgroup analysis of CSF Aβ42, t-tau, and p-tau between iNPH and AD/healthy controls
Stratification group | iNPH vs. AD | iNPH vs. healthy controls | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Comparisons | SMD [95% CI] | Heterogeneity test | Comparisons | SMD [95% CI] | Heterogeneity test | ||||||||||
Studies (NiNPH/NAD) | Z | P | Q | P | I2, % | Studies (NiNPH/NControl) | Z | P | Q | P | I2, % | ||||
Aβ42 | Total | 7 (268/186) | 1.98 | 0.05 | 0.32 (0.00, 0.63) | 11.93 | 0.06 | 50 | 6 (193/147) | 3.75 | 0.0002 | −1.14 (−1.74, −0.55) | 23.55 | 0.0003 | 79 |
Study population | |||||||||||||||
Caucasian | 5 (197/159) | 1.41 | 0.16 | 0.17 (−0.07, 0.40) | 6.47 | 0.17 | 38 | 4 (122/129) | 9.94 | <0.00001 | −1.60 (−1.91, −1.28) | 0.67 | 0.88 | 0 | |
Asian | 2 (71/27) | 3.09 | 0.002 | 0.75 (0.27, 1.22) | 0.79 | 0.37 | 0 | 2 (71/18) | 0.41 | 0.68 | −0.17 (−0.96, 0.63) | 2.26 | −0.13 | 56 | |
CSF source | |||||||||||||||
Lumbar | 5 (114/119) | 1.49 | 0.14 | 0.39 (−0.12, 0.91) | 11.41 | 0.02 | 65 | 6 (193/147) | 3.75 | 0.0002 | −1.14 (−1.74, −0.55) | 23.55 | 0.0003 | 79 | |
Ventricular | 2 (154/67) | 1.41 | 0.16 | 0.21 (−0.08, 0.50) | 0.00 | 0.95 | 5 | – | – | – | – | – | – | – | |
t-tau | Total | 8 (323/206) | 3.57 | 0.0004 | −1.26 (−1.95, −0.57) | 70.50 | <0.00001 | 90 | 6 (193/147) | 2.22 | 0.03 | −0.80 (−1.50, −0.09) | 35.00 | <0.00001 | 86 |
Study population | |||||||||||||||
Caucasian | 5 (197/159) | 2.30 | 0.02 | −0.86 (−1.60, −0.13) | 30.2 | <0.00001 | 87 | 4 (122/129) | 1.63 | 0.10 | −0.87 (−1.91, 0.17) | 34.81 | <0.00001 | 91 | |
Asian | 3 (126/47) | 4.37 | <0.00001 | −1.88 (−2.72, −1.03) | 8.69 | 0.01 | 77 | 2 (71/18) | 2.41 | 0.02 | −0.66 (−1.19, −0.12) | 0.04 | 0.84 | 0 | |
CSF source | |||||||||||||||
Lumbar | 6 (169/139) | 5.28 | <0.00001 | −1.66 (−2.28, −1.05) | 21.18 | 0.0008 | 76 | 6 (193/147) | 2.22 | 0.03 | −0.80 (−1.50, −0.09) | 35.00 | <0.00001 | 86 | |
Ventricular | 2 (154/67) | 0.83 | 0.41 | −0.12 (−0.41, 0.17) | 0.03 | 0.87 | 0 | – | – | – | – | – | – | – | |
p-tau | Total | 8 (323/206) | 3.78 | 0.0002 | −1.54 (−2.34, −0.74) | 89.64 | <0.00001 | 92 | 6 (193/147) | 8.36 | <0.00001 | −1.12 (−1.38, −0.86) | 3.4 | 0.64 | 0 |
Study population | |||||||||||||||
Caucasian | 5 (197/159) | 2.49 | 0.01 | −1.11 (−1.99, −0.24) | 40.87 | <0.00001 | 90 | 4 (122/129) | 7.9 | <0.00001 | −1.21 (−1.51, −0.91) | 1.82 | 0.61 | 0 | |
Asian | 3 (126/47) | 3.21 | 0.001 | −2.23 (−3.59, −0.87) | 20.55 | <0.00001 | 90 | 2 (71/18) | 2.99 | 0.003 | −0.83 (−1.37, −0.29) | 0.11 | 0.74 | 0 | |
CSF source | |||||||||||||||
Lumbar | 6 (169/139) | 5.42 | <0.00001 | −2.03 (−2.77, −1.30) | 27.56 | <0.00001 | 82 | 6 (193/147) | 8.36 | <0.00001 | −1.12 (−1.38, −0.86) | 3.4 | 0.64 | 0 | |
Ventricular | 2 (154/67) | 0.80 | 0.42 | −0.12 (−0.41, 0.17) | 0.00 | 0.95 | 0 | – | – | – | – | – | – | – | |